Hikma Pharmaceuticals HIK

LON: HIK | ISIN: GB00B0LCW083 26/04/2024

1.913,00 GBX (+3,18%)

(+3,18%) 26/04/2024

Grafiek Hikma Pharmaceuticals

Grafiek Hikma Pharmaceuticals

1 dag1d 3,18%
1 week1w 5,23%
1 maand1m 1,73%
3 maanden3m 0,90%
6 maanden6m 0,03%
1 jaar1j 8,08%
5 jaar5j 10,77%

Hikma Pharmaceuticals in het nieuws

Toon enkel gratis nieuws

21 februari 2024 · Hikma hosts White House Drug Policy Director Dr. Rahul Gupta at its Columbus, Ohio manufacturing facility · Persbericht

5 februari 2024 · Hikma announces US launch of COMBOGESIC® IV · Persbericht

3 oktober 2023 · Hikma marks two-year anniversary of KLOXXADO® launch by surpassing 375,000 doses donated in the US · Persbericht

10 augustus 2023 · Rakuten Medical and Hikma Sign Exclusive Licensing Agreement for Alluminox™ Platform Cancer Treatment in the Middle East and North Africa · Persbericht

26 juli 2023 · Hikma Ventures invests in Octave Bioscience, a precision care platform for Multiple Sclerosis and other neurodegenerative diseases · Persbericht

15 juni 2023 · Hikma exceeds 150 injectable medicines in the US with launch of Dobutamine Injection, USP · Persbericht

9 maart 2023 · Hikma expands impact in Canada with launches of new sterile injectable medicines · Persbericht

30 augustus 2022 · Hikma launches RYALTRIS™ seasonal allergic rhinitis nasal spray in the US · Persbericht

Profiel Hikma Pharmaceuticals

Farmaceutische Producten: Generisch

Gezondheidstechnologie

Medicinale en botanische productie

CEO: Sigurdur Olafsson

Aandelen Hikma Pharmaceuticals

Beurswaarde: 4,11 miljard GBP

Effecten: 221,89 miljoen

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe